Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

NCT00003984 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

BIOLOGICAL: lintuzumab

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC